Concepedia

Mireya Fernández-Fournier

MF

Statistics

Publications

8

Citations

1.2K

H-Index

8

Active since

2016

Affiliations

Alexion Pharmaceuticals (United States)(Current)

Fondazione IRCCS Istituto Neurologico Carlo Besta

International University of Health and Welfare

University of North Carolina at Chapel Hill

National Hospital Organization Hanamaki Hospital

Mireya Fernández-Fournier is an author at Alexion Pharmaceuticals (United States) specializing in medicine, pharmacology, and anti-acetylcholine receptor antibodies.

ORCID

Publications per year

2016–2025

8

Publications

8

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

Neuromyelitis optica spectrum disorders

María Sepúlveda, Thaís Armangué, Núria Solà‐Valls et al. · Neurology Neuroimmunology & Neuroinflammation · 2016 · 152 citations · Full text

, , +14

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

, , +14

Brain and immune system-derived extracellular vesicles mediate regulation of complement system, extracellular matrix remodeling, brain repair and antigen tolerance in Multiple sclerosis

Gabriel Torres Iglesias, Mireya Fernández-Fournier, Lucía Botella et al. · Brain Behavior and Immunity · 2023 · 43 citations · Full text

, , +17

1–5 of 8